All In Biotech

Drug Trial Radar · NCT06949124

A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects

A Single-center, Single-arm, Open-label, Fixed-sequence, Self-controlled Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of SHR7280 and Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Apr 28, 2025

Primary completion

Jun 5, 2025

Study completion Jun 5, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effects of SHR7280 on the pharmacokinetics of midazolam, S-warfarin, omeprazole, digoxin and rosuvastatin in healthy subjects.

Conditions

  • Endometriosis
  • Uterine Fibroids
  • Assisted Reproduction

Interventions

  • SHR7280 TabletsDrug

    SHR7280 tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum concentration (Cmax)Time frame: 0 to anticipated 29 days.
  2. Area under the curve from time 0 to infinity (AUC0-∞)Time frame: 0 to anticipated 29 days.
  3. Area under the curve from time 0 to time t (AUC0-t)Time frame: 0 to anticipated 29 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongnan hospital of Wuhan University

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.